July 4, 2014
Otsuka Pharmaceutical Co., Ltd.
E Keppra® Injectable Receives Marketing Authorization in Japan
Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged Four and Over
- Approval of E Keppra® IV Drip Infusion use will enable uninterrupted treatment of patients temporarily unable to swallow oral E Keppra® formulations. This product has been approved in over 40 countries and regions including in the EU and US in 2006.
- About 1% of people worldwide have epilepsy, and onset of new cases is particularly high in infants and the elderly. About 70% of patients can live seizure-free lives if they are able to continuously take anti-epileptic drugs.
- E Keppra® (brand name outside Japan is Keppra®) was first approved in the US in 1999 and has received approval in more than 100 countries and regions. It is a novel anti-epileptic drug prescribed to patients ranging from children to the elderly. It has been used by more than 100,000 patients in Japan.
Otsuka Pharmaceutical Co., Ltd. (headquarters: Tokyo; President and Representative Director: Taro Iwamoto;) and UCB Japan Co., Ltd. (headquarters: Tokyo; President and Representative Director: Joel Peterson) received marketing authorization in Japan on July 4, 2014, 2014 for E Keppra® for IV Drip Infusion 500 mg (levetiracetam). E Keppra® IV Drip Infusion is an alternative for patients who are temporarily unable to take oral formulations of E Keppra®.
Information in this news release was current as of the original release date.